AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11915854
Drug: CEE 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 1.25 mg/day
Trial: 7718674
Drug: Clomipramine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (12.5 mg, i.v.)
Trial: 2167788
Drug: Aspirin infusion
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin infusion at 1 mumol/l
Trial: 2167788
Drug: Aspirin infusion
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin infusion at 2 mumol/l
Trial: 2167788
Drug: Aspirin infusion
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin infusion at 4 mumol/l
Trial: 2167788
Drug: Aspirin infusion
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin infusion at 0 mumol/l (control)
Trial: 7232461
Drug: Secobarbital (30-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secobarbital (30-300 mg)
Trial: 7232461
Drug: Chlorpromazine (25-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (25-100 mg)
Trial: 22736123
Drug: Individualized fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized fluid therapy
Trial: 18525035
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (single‐dose nevirapine plus 1 week of zidovudine)
Trial: 12079630
Drug: 1.45 microm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.45 microm diode laser treatment with an average power of 12 W, heating times from 150 ms to 500 ms, applied over two to six treatment cycles.
Trial: 7564350
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg quinapril plus 12.5 mg hydrochlorothiazide (HCTZ)
Trial: 7564350
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg quinapril monotherapy
Trial: 7564350
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg hydrochlorothiazide (HCTZ) monotherapy
Trial: 7564350
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (quinapril + HCTZ)
Trial: 2209135
Drug: Bendrofluazide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide plus triamterene 200 mg
Trial: 2209135
Drug: Bendrofluazide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide plus spironolactone 100 mg
Trial: 2209135
Drug: Bendrofluazide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide plus triamterene 50 mg
Trial: 2209135
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose triamterene
Trial: 7188585
Drug: Prizidilol (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prizidilol (400-800 mg/day)
Trial: 7188585
Drug: Prizidilol (mean:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prizidilol (mean: 447 mg once daily)
Trial: 7188585
Drug: Prizidilol (mean:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prizidilol (mean: 700 mg once daily)
Trial: 31117809
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) sinus implant (1350 mcg) and MF nasal spray (MFNS)
Trial: 31117809
Drug: MF nasal
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF nasal spray (MFNS) alone
Trial: 29072002
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with oral loxoprofen sodium tablets (60 mg, twice a day, for one week)
Trial: 29072002
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups showed significant decrease in ROM and VAS scores post-treatment (P<0.01)
Trial: 23941282
Drug: Modified balloon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified balloon dilatation treatment and regular dysphagia therapy
Trial: 23941282
Drug: Regular dysphagia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dysphagia therapy only
Trial: 19835591
Drug: Alternative medication
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative medication (BTA or saline) for non-responders in subgroups C and D
Trial: 14964681
Drug: Prompt‐L‐Pop (PLP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt‐L‐Pop (PLP)
Trial: 6239300
Drug: Dextroamphetamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (0.3 mg/kg IV) with Haloperidol (0.014 mg/kg IM)
Trial: 6239300
Drug: Dextroamphetamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (0.3 mg/kg IV) with Propranolol (0.1 mg/kg IV)
Trial: 6239300
Drug: Dextroamphetamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (0.3 mg/kg IV) with Thymoxamine (0.1 mg/kg IV)
Trial: 6239300
Drug: Dextroamphetamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (0.3 mg/kg IV) with Placebo
Trial: 27206564
Drug: Fentanyl iontophoretic
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl iontophoretic transdermal system (fentanyl ITS, IONSYS)
Trial: 27206564
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia morphine (IV PCA morphine)
Trial: 23026438
Drug: Umeclidinium 250
RxNorm normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium 250 μg
Trial: 23026438
Drug: Umeclidinium 500
RxNorm normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium 500 μg
Trial: 16887429
Drug: Neridronate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neridronate treatment (2 mg/kg administered intravenously for 2 consecutive days, every 3 months)
Trial: 14962524
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (16 mmol over 15 min and then 65 mmol over 24 h)
Trial: 11298538
Drug: 0.2% SDZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% SDZ ASM 981 cream
Trial: 11298538
Drug: 0.6% SDZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6% SDZ ASM 981 cream
Trial: 11298538
Drug: 1.0% SDZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% SDZ ASM 981 cream
Trial: 11298538
Drug: 0.1% betamethasone-17-valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% betamethasone-17-valerate cream (BMV)
Trial: 9613279
Drug: Whoosh test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whoosh test (injection of air into the caudal epidural space)
Trial: 7924125
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day cetirizine
Trial: 7924125
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day cetirizine
Trial: 1100055
Drug: Catalase (Optidase)
RxNorm normalized name: catalase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catalase (Optidase) injections
Trial: 1100055
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without catalase
Trial: 1100055
Drug: Catalase (Optidase)
RxNorm normalized name: catalase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catalase (Optidase) injections in extended study
Trial: 16836774
Drug: Child-friendly constraint-induced
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-friendly constraint-induced movement therapy (CI therapy); 6 hours per day for 10 out of 12 consecutive days
Trial: 16836774
Drug: Child-friendly constraint-induced
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-friendly constraint-induced movement therapy (CI therapy)
Trial: 12015761
Drug: THP (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THP (30 mg/30 mL of normal saline) administered into the bladder within 6 hours after TUR‐Bt
Trial: 11382659
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (600 mg/d)
Trial: 2033528
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine gluconate (CHX) rinse, 15 ml b.i.d. for 7 weeks (2 weeks before crown preparation, 3 weeks during provisional crown placement, 2 weeks after definitive crown cementation)
Trial: 2033528
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal oral hygiene without CHX)
Trial: 26654154
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC) 600 mg, three times a day for 24 weeks
Trial: 26654154
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg, three times a day for 24 weeks
Trial: 24928634
Drug: EGFR stages
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR stages >90 ml min‐1 1.73 m‐2
Trial: 24928634
Drug: EGFR stages
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR stages <60 ml min‐1 1.73 m‐2
Trial: 24928634
Drug: EGFR stages
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR stages <45 ml min‐1 1.73 m‐2
Trial: 16247062
Drug: Epley procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Epley procedure with self-treatment
Trial: 16247062
Drug: self-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: self-treatment
Trial: 10939030
Drug: Epirubicin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 150 mg/m2-cisplatin (group A)
Trial: 10939030
Drug: Epirubicin 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 180 mg/m2-cisplatin (group B)
Trial: 8748403
Drug: Daily lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily lithium carbonate treatment (700 mg)
Trial: 8748403
Drug: Alternate-day lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day lithium carbonate treatment (1200 mg)
Trial: 1710167
Drug: ThioTEPA at
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ThioTEPA at 75 mg/m2
Trial: 1710167
Drug: ThioTEPA at
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ThioTEPA at 65 mg/m2
Trial: 1710167
Drug: ThioTEPA pharmacokinetics
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ThioTEPA pharmacokinetics
Trial: 1710167
Drug: TEPA pharmacokinetics
RxNorm normalized name: Tepadina
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TEPA pharmacokinetics
Trial: 7018798
Drug: Methandienone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methandienone (100 mg/day)
Trial: 31017453
Drug: Traditional and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional and Complementary Medicine (T&CM) interventions in addition to nicotine replacement therapy (NRT) and counseling
Trial: 31017453
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (NRT) and counseling
Trial: 27570900
Drug: Metacognitive Reflection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive Reflection and Insight Therapy (MERIT) - 12 sessions
Trial: 22755543
Drug: Sevoflurane plus
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane plus low-dose remifentanil (Group SR)
Trial: 18041570
Drug: 4 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml/kg of hypertonic-hyperoncotic solution (7.2% NaCl/10% dextran)
Trial: 16120066
Drug: Indinavir alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir alone or in combination with ritonavir
Trial: 10599886
Drug: Wild-type IL-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wild-type IL-4 receptor
Trial: 7476738
Drug: Inhalation anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthesia using N2O:O2, halothane, d‐tubocurarine (n = 11)
Trial: 7476738
Drug: Inhalation anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthesia using N2O:O2, halothane, d‐tubocurarine, and supplemented with epidural analgesia (EA) (n = 11)
Trial: 7476738
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) using ketamine 10‐30 ug.kg‐1.min‐1, propofol 2 mg.kg‐1.h‐1, d‐tubocurarine, and supplemented with continuous EA (n = 6)
Trial: 7476738
Drug: TIVA using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA using ketamine 20‐50 ug.kg‐1.min‐1, midazolam in increments of 1.5 to 5 mg, and supplemented with intermittent EA (n = 5)
Trial: 6752876
Drug: Ketoprofen (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (300 mg/day)
Trial: 30176553
Drug: BCS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCS plus postoperative radiation therapy (XRT)
Trial: 25259787
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus low-dose rosiglitazone (MR)
Trial: 21180001
Drug: RelyX ARC
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RelyX ARC (ARC, 3M ESPE) with 32% phosphoric acid treatment
Trial: 17708284
Drug: Low-dose anticancer
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose anticancer drugs (MMC 2-8 mg, EPI 5-10 mg, CBP 100 mg)
Trial: 17708284
Drug: Conventional-dose anticancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose anticancer drugs (MMC 10 mg, EPI 40 mg, CBP 300 mg)
Trial: 12172338
Drug: Reboxetine 8
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 8 to 10 mg per day
Trial: 8271293
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of beta carotene per day
Trial: 8271293
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g ascorbic acid plus 400 mg alpha tocopherol per day
Trial: 8271293
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three agents combined (25 mg beta carotene, 1 g ascorbic acid, 400 mg alpha tocopherol)
Trial: 8271293
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three agents combined
Trial: 2536257
Drug: Dideoxycytidine 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dideoxycytidine 0.06 mg/kg
Trial: 2536257
Drug: Dideoxycytidine 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dideoxycytidine 0.03 mg/kg
Trial: 2536257
Drug: Dideoxycytidine 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dideoxycytidine 0.01 mg/kg
Trial: 2536257
Drug: Dideoxycytidine 0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dideoxycytidine 0.005 mg/kg
Trial: 29330230
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention including bimonthly behavioural counselling, sit-stand desk attachment, wrist-worn activity-prompting device, cognitive behavioural therapy for LBP self-management
Trial: 22800624
Drug: Low-dose iron
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose iron supplementation (1 mg×kg⁻¹×d⁻¹) for 2 months
Trial: 3579819
Drug: Alcohol at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol at ground level (100-proof vodka mixed with juice, 2.2 ml X kg-1 of body weight)
Trial: 31840620
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid (FA) at 10 mg FA/kg dietary DM
Trial: 31840620
Drug: Branched-chain volatile
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain volatile fatty acids (BCVFA) at 5 g BCVFA/kg dietary DM
Trial: 31840620
Drug: Combined addition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined addition of FA and BCVFA (10 mg/kg DM of FA and 5 g/kg DM of BCVFA)
Trial: 23475448
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO), twice-daily sessions for 90 minutes at 2.5 ATA, 5 days a week for 2 weeks.
Trial: 21981360
Drug: 532-nm KTP
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 532-nm KTP laser treatment (once weekly)
Trial: 21981360
Drug: 532-nm KTP
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 532-nm KTP laser treatment (twice weekly)
Trial: 2097909
Drug: Topical benzocaine
RxNorm normalized name: benzocaine Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzocaine 20%
Trial: 19769421
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lidocaine, tetracaine, and phenylephrine
Trial: 19769421
Drug: Topical anesthetics
RxNorm normalized name: topical anesthetics (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthetics (both)
Trial: 15564204
Drug: Itraconazole plus
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole plus lactobacillus preparation for 8 weeks
Trial: 15564204
Drug: Lactobacillus preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus preparation alone for 8 weeks
Trial: 6228469
Drug: Heat-inactivated hepatitis
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated hepatitis B vaccine (3 micrograms-HBsAg)
Trial: 6228469
Drug: Heat-inactivated hepatitis
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated hepatitis B vaccine
Trial: 24187861
Drug: Integrated Chinese-Western
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Chinese-Western therapy (injection and prescriptions of Chinese medicine based on Traditional Chinese Medicine syndrome differentiation, combined with Western treatment)
Trial: 24187861
Drug: Western therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western therapy alone (chemotherapy, supportive treatment, and symptomatic treatment)
Trial: 24187861
Drug: Integrated Chinese-Western
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Chinese-Western therapy
Trial: 21264527
Drug: Anti-adrenergic medications
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-adrenergic medications
Trial: 15111772
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m(2)) followed by Paclitaxel (200 mg/m(2) over 3 h)
Trial: 15111772
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m(2)) followed by Cyclophosphamide (600 mg/m(2))
Trial: 9625042
Drug: Sodium dodecyl
RxNorm normalized name: Sodium dodecyl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium dodecyl sulfate‐agarose gel electrophoresis (SDS‐AGE)
Trial: 9625042
Drug: Routine agarose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine agarose gel electrophoresis (AGE)
Trial: 18070142
Drug: Nitroglycerine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine infusion
Trial: 2512162
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration of NTG 20 mg (24 h)‐1 patches with a 12-hour nitrate-free interval
Trial: 2512162
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with NTG 20 mg (24 h)‐1 patches